STOCK TITAN

Revance Therapeu - RVNC STOCK NEWS

Welcome to our dedicated page for Revance Therapeu news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeu stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revance Therapeu's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revance Therapeu's position in the market.

Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) presented two posters at the AAN meeting on DAXXIFY® for cervical dystonia treatment. Data showed customizable retreatment intervals and benefits of DAXXIFY's formulation. The studies suggest long-acting symptom control, low adverse event rates, and potential for tailored treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
conferences
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) grants 222,452 RSUs to 29 new employees, with vesting over four years, subject to continued service. The awards were approved by the Compensation Committee as inducements for employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) priced an underwritten public offering of 16 million shares of common stock at $6.25 per share, expecting to raise $100 million in gross proceeds. The offering is set to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) announces a proposed underwritten public offering of $100 million of its common stock, with an option for additional shares. The company plans to utilize the proceeds for commercial growth, product launches, and general corporate purposes. Barclays is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) reported strong financial results for Q4 and full year 2023, with product revenue reaching $58.5 million and $212.7 million, respectively. The company achieved significant YoY growth of 28% and 80%. The 2024 revenue guidance stands at $280 million, showcasing blockbuster potential in U.S. aesthetics. DAXXIFY for cervical dystonia is on track for a mid-year launch, with positive financial outlook and a focus on achieving positive Adjusted EBITDA in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.15%
Tags
-
Rhea-AI Summary
Revance Therapeutics (RVNC) to Release Q4 and Full Year 2023 Financial Results on February 28, 2024, with a Conference Call and Webcast to Discuss Results and Corporate Update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) announces participation in upcoming investor conferences with key executives presenting fireside chats. CEO Mark Foley and CFO Tobin Schilke to present at Cowen 44th Annual Healthcare Conference on March 5, 2024, and CEO Mark Foley at Barclays Global Healthcare Conference on March 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) has received a permanent J-code for DAXXIFY, a treatment for cervical dystonia, streamlining reimbursement. The pivotal Phase 3 study results published in Neurology reinforce the product's long duration of effect and favorable safety profile. The study showed that DAXXIFY was effective, generally safe, and well-tolerated, with a median duration of effect of over 20 weeks. The U.S. therapeutic neuromodulator market opportunity for DAXXIFY is $2.7 billion, including the over $350 million cervical dystonia market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference on February 7-8, 2024, in New York. CEO Mark J. Foley will be participating in a fireside chat on February 8 at 9:30a.m. EST. The live audio webcast will be available on the company's website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
conferences
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) reports a 22% increase in Q4 DAXXIFY® volume sold over Q3, with a projected 2024 product revenue guidance of at least $280 million. Preliminary unaudited Q4 and full year 2023 product revenue for DAXXIFY and RHA® Collection is estimated to be between $58 million and $59 million and $212 million and $213 million, respectively, representing approximately 28% and 80% YoY growth. The company expects to achieve positive Adjusted EBITDA in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.57%
Tags
Revance Therapeu

Nasdaq:RVNC

RVNC Rankings

RVNC Stock Data

381.02M
95.41M
8.56%
87.45%
4.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
NASHVILLE